text
"['\n1. 요약재무정보\n가. 연결 재무정보\n1) 요약재무정보(연결)\xa0\n(단위 : 원 )\n구 분\n제64기\n제63기\n제62기\n[유동자산]\n28,588,864,538\n23,933,161,412\n32,335,811,726\nㆍ당좌자산\n22,661,279,742\n15,830,750,836\n22,324,638,175\nㆍ재고자산\n5,927,584,796\n8,102,410,576\n10,011,173,551\n[비유동자산]\n42,458,018,123\n52,209,349,714\n51,753,184,638\nㆍ투자자산\n7,573,921,535\n4,808,645,719\n5,803,907,176\nㆍ유형자산\n29,399,326,805\n37,192,300,892\n41,668,859,785\nㆍ무형자산\n474,531,521\n2,208,933,367\n2,646,703,007\nㆍ기타비유동자산\n5,010,238,262\n7,999,469,736\n1,633,714,670\n자산총계\n71,046,882,661\n76,142,511,126\n84,088,996,364\n[유동부채]\n13,695,602,065\n13,032,311,572\n14,918,333,308\n[비유동부채]\n7,742,853,098\n9,847,745,051\n6,524,272,722\n부채총계\n21,438,455,163\n22,880,056,623\n21,442,606,030\n[지배기업의 소유주에게 귀속되는 자본]\n49,608,155,461\n53,262,300,152\n64,787,134,464\nㆍ자본금\n59,286,024,500\n50,899,498,000\n114,267,552,000\nㆍ연결자본잉여금\n9,514,139,231\n8,888,909,782\n3,227,318,552\nㆍ연결기타자본항목\n(524,477,868)\n261,152,333\n8,630,005,372\nㆍ연결이익잉여금\n(18,667,530,402)\n(6,787,259,963)\n(61,337,741,460)\n[비지배지분]\n272,037\n154,351\n(2,140,744,130)\n자본총계\n49,608,427,498\n53,262,454,503\n62,646,390,334\n매출액\n52,020,405,167\n37,214,177,862\n30,373,353,893\n영업이익(손실)\n2,308,773,750\n(12,361,005,153)\n(10,123,767,392)\n연결당기순이익(손실)\n(15,274,852,893)\n(12,759,326,319)\n(30,174,299,094)\n지배회사지분 순이익(손실)\n(15,274,984,906)\n(11,996,066,386)\n(19,505,949,555)\n보통주 기본주당순이익(손실)\n(135)\n(116)\n(112)\n보통주 희석주당순이익(손실)\n(135)\n(116)\n(112)\n연결에 포함된 회사수\xa0\xa0 (단위 : 개)\n2\n2\n2\n※ 한국채택국제회계기준 작성기준에 따라 작성되었습니다.\xa0\xa0\n2)재무제표 재작성- 해당 없음 -\n3) 당기에 신규로 연결재무제표에 포함된 종속기업이나 당기 중 연결재무제표의 작성대상에서 제외된 종속기업은 다음과 같습니다.\xa0 \xa0\n회계기준\n제64기\n제63기\n제62기\n한국채택국제회계기준(K-IFRS)적용 시\nORIENT SCIENCE & HEALTHCARE, INC.Orient Bioresource Center Inc\nORIENT SCIENCE & HEALTHCARE, INC.Orient Bioresource Center Inc\nORIENT SCIENCE & HEALTHCARE, INC.Orient Bioresource Center Inc\n4) 연결재무제표 작성 기준- 자세한 사항은 \'3. 연결재무제표 주석\'을 참조 바랍니다.\xa0\n나. 별도 재무정보\n1) 요약 재무정보(별도)\xa0\n(단위 : 원 )\n구 분\n제64기\n제63기\n제62기\n[유동자산]\n22,744,621,414\xa0\n22,105,987,658\n33,043,976,531\nㆍ당좌자산\n17,634,949,147\xa0\n16,904,087,349\xa0\n26,016,424,616\nㆍ재고자산\n3,473,235,625\xa0\n3,629,453,520\xa0\n6,884,426,799\nㆍ기타유동자산\n1,636,436,642\xa0\n1,572,446,789\xa0\n143,125,116\n[비유동자산]\n40,212,480,419\xa0\n48,213,404,324\xa0\n55,039,362,875\nㆍ투자자산\n15,112,667,456\xa0\n11,909,167,950\xa0\n5,804,691,806\nㆍ유형자산\n19,615,043,180\xa0\n26,095,833,271\xa0\n31,137,265,312\nㆍ무형자산\n474,531,521\xa0\n2,208,933,367\xa0\n2,646,703,007\nㆍ기타비유동자산\n5,010,238,262\xa0\n7,999,469,736\xa0\n15,450,702,750\n자산총계\n62,957,101,833\xa0\n70,319,391,982\xa0\n88,083,339,406\n[유동부채]\n12,933,023,628\xa0\n10,516,224,051\xa0\n14,334,056,074\n[비유동부채]\n7,742,853,098\xa0\n9,847,745,051\xa0\n6,233,963,052\n부채총계\n20,675,876,726\xa0\n20,363,969,102\xa0\n20,568,019,126\n[자본금]\n59,286,024,500\xa0\n50,899,498,000\xa0\n114,267,552,000\n[자본잉여금]\n3,852,548,001\xa0\n3,227,318,552\xa0\n3,227,318,552\n[기타자본항목]\n164,052,647\xa0\n173,053,395\xa0\n183,069,539\n[이익잉여금]\n(21,021,400,041)\n(4,344,447,067)\n(50,162,619,811)\n자본총계\n42,281,225,107\xa0\n49,955,422,880\xa0\n67,515,320,280\n종속·관계·공동기업투자주식의 평가방법\n원가법\n원가법\n원가법\n2020년4월부터2021년3월까지\n2019년4월부터2020년3월까지\n2018년4월부터2019년3월까지\n매출액\n25,191,324,559\xa0\n23,026,306,643\xa0\n26,717,684,075\xa0\n영업이익(손실)\n(4,745,328,394)\n(9,712,026,775)\n(7,106,603,047)\n당기순이익(손실)\n(19,957,073,500)\n(20,626,424,531)\n(21,365,618,595)\n보통주 기본주당순이익(손실)\n(176)\n(196)\n(122)\n보통주 희석주당순이익(손실)\n(176)\n(196)\n(122)\n※ 한국채택국제회계기준 작성기준에 따라 작성되었습니다.(별도 기준) 2) 재무정보 이용상의 유의점 (별도재무제표 기준)- 전기에 제출된 사업보고서의 첨부자료 ""5. 재무제표 주석""을 참조바랍니다.\xa0\n']"
